New imaging tracer for metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new radioactive tracer that may help doctors see and treat prostate cancer that has spread. The tracer attaches to cancer cells so they show up on scans, and may also help guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man between 18 and 85 years old.
- Your doctor expects you to live at least 12 more weeks.
- You have not had chemotherapy or radiation therapy yet.
- You have at least one tumor that can be measured on a scan.
- Your liver and kidney function must be close to normal.
- You must be able to lie still for 30 minutes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a European registry that collects information from men with prostate cancer who need advanced imaging (like PSMA PET/CT or MRI) to check if the cancer has spread. By joining, you help researchers learn more about how these scans improve care.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
This study uses special PET scans (up to 4 times) to see how metastatic prostate cancer changes over time. It is for people whose cancer has spread and is still growing after hormone treatments, and who are planning to start chemotherapy or PSMA therapy.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
Hear when a new Metastatic Prostate Cancer (mPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.